Just went back and read a Seeking Alpha post from 12-20-12 from a few days before approval. The analyst cited in the article had these projections. Calender years.....For US only...
He also said that EU sales would probably be about 50% of US levels, so I guess that implies adding 50% to the above estimates. With TEVA now on board, these levels could be higher with their marketing expertise, possible addl indications, etc.
they could do 150mm in year one with teva ... that 30mm plus in royalites plus 100mm in milestone payments. lots of guesswork and hope in these numbers. but its possible. once teva figures out how to use this delevery platform for other drugs ALXA will be a billion dollar company.